Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 1;34(6):544-552.
doi: 10.1097/MOP.0000000000001172. Epub 2022 Sep 9.

Prenatal genetic testing 1: screening tests

Affiliations
Review

Prenatal genetic testing 1: screening tests

Morgan Jenkins et al. Curr Opin Pediatr. .

Abstract

Purpose of review: Prenatal genetic testing can be divided into two categories: screening and diagnostic. This article will focus on reviewing prenatal genetic screening tests.

Recent findings: Cell-free DNA (cfDNA) is a new prenatal genetic screening test with a high degree of accuracy for identifying certain genetic conditions like trisomy 21, 18, and 13. However, cfDNA has also been applied in the screening of other genetic conditions without similar research support.

Summary: Prenatal genetic screening evaluates at risk pregnancies - including both carrier screening, which can be done at any point in a person's life, and aneuploidy screening, which is done during pregnancy. Within screening, there is a new noninvasive technology that has revolutionized prenatal screening called cfDNA testing. Compared to previous methods, this technology is easier to administer and more accurate for certain genetic conditions. However, cfDNA has also been applied to test for less common genetic conditions without efficacious research support. In this time of expansion in genetic testing, it is important that providers educate themselves on the research support behind each type of genetic test. It is vital that professional organizations continuously update their testing approach to match these rapidly evolving technologies and the patient population they serve.

PubMed Disclaimer

Comment in

  • Editorial: Prenatal genetic testing.
    Jenkins M, Seasely AR, Subramaniam A, Robin NH. Jenkins M, et al. Curr Opin Pediatr. 2022 Dec 1;34(6):531-532. doi: 10.1097/MOP.0000000000001175. Curr Opin Pediatr. 2022. PMID: 36321220 No abstract available.

Similar articles

Cited by

References

    1. Lea D, Kaphingst K, Bowen D, et al. Communicating genetic and genomic information: health literacy and numeracy considerations. Public Health Genomics 2011; 14:279–289.
    1. Gregg A, Edwards J. Prenatal genetic carrier screening in the genomic age. Semin Perinatol 2018; 42:303–306.
    1. Gregg A. Expanded carrier screening. Obstet Gynecol Clin North Am 2018; 45:103–112.
    1. The American College of Obstetricians and Gynecologists (n.d.). Prenatal genetic screening tests. Available at: https://www.acog.org/womens-health/faqs/prenatal-genetic-screening-tests [retrieved 1 May 2022].
    1. Gregg A, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021; 23:1793–1806.

Substances